The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

Amgen Inc. is at least fairly valued, with improving balance sheet metrics and a robust growth pipeline offsetting looming ...

On December 3, BMO Capital’s Evan Seigerman increased the firm’s price target on Amgen Inc. (NASDAQ:AMGN) to $372 from $335 ...

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Evercore 8th Annual Healthcare Conference December 3, 2025 10:00 AM ESTCompany ParticipantsPeter Griffith - Executive VP & ...

Amgen Inc. stock has reached a new 52-week high, hitting $345.95, marking a significant milestone for the biotechnology company. The stock is now trading just 0.99% from its 52-week high of $345.84.

Amgen Inc. (NASDAQ:AMGN) ranks among the Best Low Volatility Investments in December 2025. Goldman Sachs reaffirmed its $400 ...

Amgen’s AMGN stock has risen almost 16% in a month. A lot of this price increase is due to strong third-quarter 2025 results, ...

The next-generation “GLP-1 plus” drugs will be tailored to the health needs of individual patients.

Len Yaffee says Eli Lilly stock will find it hard to push any higher from here. The Kassef Capital's chief executive explained why in a recent CNBC interview. LLY shares are already up a whopping 75% ...

Ozempic, and the class of weight loss drugs it has come to embody, has left its imprint seemingly everywhere: On the lives of ...